Final Program [International AIDS Society (11th: 1996: Vancouver, Canada)]

VENUE ROOM TRACK SESSION NO. TIME I SESSION PATHWAYS
A2 222 Track A: Basic Science
Room Abstract Session:
8/I5 Immunotherapy
Chairs:
Sean Hosein, Canada / Marjorie Robert-Guroff, USA...............................................................................................................................................................................................................................................
Tu.A.270 13:30
IMREG-I AND IMREG-2:TWO INVESTIGATIONAL IMMUNE-BASED THERAPEUTICS THAT MODULATE
CELL-MEDIATED IMMUNITY
Gottlieb, A Arthur/2, Sizemore RI, Kern C', Gottlieb M2. 'Tulane University School of Medicine; 2lmreg, Inc., New Orleans, LA, USA................................................................................................................................................................................................................................................
Tu.A.271 13:45
ANTIVIRAL EFFECT FROM THE CD28 COSTIMULATORY RECEPTOR MEDIATES EXVIVO CD4+ T CELL EXPANSION r.
FROM PATIENT WITH HIV-I INFECTION
June, Carl2, St. Louis DCI, Levine B2, Mosca j', Riley J2, Carroll RI, Lin JTI,Vahey M2, Jagodzinski LI,Wagner K', Mayers D2, Burke D2,
Weislow 02. 'Henry M. Jackson Foundation; 2Military Medical Consortium for Applied Retroviral Research, Rockville, MD, USA................................................................................................................................................................................................................................................
Tu.A.272 14:00
INTERLEUKIN-13 RECEPTOR:A NEW TARGET FORA PSEUDOMONAS EXOTOXIN BASED CHIMERIC PROTEIN ON
AIDS-ASSOCIATED KAPOSI'S SARCOMA CELLS
Husain, Syed R', Obiri N', Gill p2, Pastan 13, Debinski W4, Puri RKi. IFDA, Center for Biologics Evaluation & Research, Bethesda, MD;
2University of Southern California, Los Angeles, CA; 3National Cancer Institute, Bethesda, MD; 4Milton S. Hershey Medical Center,
Hershey PA, USA................................................................................................................................................................................................................................................
Tu.A.273 14:15
SPECIFIC T-CELL RESPONSES IN HIV- I INFECTED PATIENTS IMMUNIZED WITH A RECOMBINANT HIV- I gp 160 VACCINE
Leandersson, Ann-Charlotte2, Bratt G3, Fredriksson M2, Gilljam G2, Hinkula ji, Nordlund S2, Sandstrom E2,Wahren B2. IKarolinska
Institute; 2Swedish Institute for Infectious Disease Control & 3South Hospital, Stockholm, Sweden................................................................................................................................................................................................................................................
Tu.A.274 14:30
ACTIVE IMMUNIZATION OF PATIENTS WITH HIV INFECTION:A CONTROLLED STUDY OF THE EFFECT OFVAXSYN
ON PROGRESSION OF IMMUNE DEFICIENCY
Tsoukas, Chris M, Raboud J, Schlech W Thomas R, Fong I, Rachlis A, Gill J, Montaner JSG, Lee S, Freedman J, Poon MC, Lafreniere R,
Cassol S, Djurdev O, Smith G.The Canadian HIVTrials Network; MicroGeneys Inc., Meriden, USA.
0O
U............................................................................................................................................................................................................................................... U -
Tu.A.275 14:45>
RESULTS OF A PHASE II DOUBLE-BLINDED, MULTI-CENTER, PLACEBO-CONTROLLED HIV THERAPEUTIC VACCINE TRIAL
Birx, Deborah LI, Davis C2, Ruiz N3,Tramont E4,Tacket C4, Poretz Ds,Yangco B6, Henry D7, Pierce PF8, KerkeringT9, Gordin F'o -
Thompson Mi', Luskin-Hawk RI2,Yarrish R'3, Holloway W14, Deyton L's, Robb MI, Sitz K', Kim ji6, Loomis-Price L3, Kim S3, Michael N', c
Burke DSI, Redfield RR'6. 'WRAIR; 2HM.JF; 3Dept. of the Army; 4University of Maryland, Baltimore, MD; 51HV, Maryland; 61DP Virginia; 0
71DRI Florida; 8Graduate Hospital, Philadelphia, PA; 9Georgetown UMC; 'oRichmond AIDS Consortium; I IWashington VA; I2ARCA
Atlanta; '3AIDS Research Alliance, IL; '4St.Vincent's Hospital, New York; 'sDelaware CPCRA; I6NIH, Bethesda, MD, USA.
O
U. _0g
Ca)
C
X

135